Abstract
BackgroundThe aim of this study is to investigate the expressions of somatostatin receptor (SSTR), SSTR-2, SSTR-3, and SSTR-5, in pancreatic tissue and non-cancerous tissue and elucidate their clinical significance.MethodsThe expression of somatostatin receptor subtypes SSTR-2, SSTR-3, and SSTR-5 messenger RNA (mRNA) in 108 cases of cancer tissue and adjacent tissue in patients with pancreatic cancer was detected by reverse transcriptase polymerase chain reaction (RT-PCR). Expression of SSTR-2, SSTR-3, and SSTR-5 mRNA was evaluated after specimens were taken from selected patients who underwent surgical resection by Whipple’s operation. We speculated the clinical significance of the expression of somatostatin receptor (SSTR) subtype genes SSTR-2, SSTR-3, and SSTR-5 in pancreatic tissue and non-cancerous tissue and further elucidated their clinical significance.ResultsThe expression rates of SSTR-2 mRNA in cancer and adjacent tissue of 108 patients with pancreatic cancer were 81.5% (88/108) and 97.2% (105/108), respectively; SSTR-3 mRNA expression rates were 69.4% (75/108) and 55.6% (60/108). SSTR-5 mRNA expression rates were 13.0% (14/108) and 18.5% (20/108).ConclusionWe propose that SSTR-2 plays an important role in clinical implications for patients with pancreatic cancer undergoing somatostatin or its analog therapy.Electronic supplementary materialThe online version of this article (doi:10.1186/s12957-015-0467-z) contains supplementary material, which is available to authorized users.
Highlights
The aim of this study is to investigate the expressions of somatostatin receptor (SSTR), SSTR-2, SSTR-3, and SSTR-5, in pancreatic tissue and non-cancerous tissue and elucidate their clinical significance
The expression rates of SSTR-2 messenger RNA (mRNA) in cancer and adjacent tissue of 108 patients with pancreatic cancer were 81.5% (88/108) and 97.2% (105/108), respectively; SSTR-3 mRNA expression rates were 69.4% (75/108) and 55.6%
Recent studies have indicated that somatostatin and its analogs have obvious anti-proliferative effects on various solid tumors, such as gastroenteropancreatic neuroendocrine tumors and breast cancer, which are mediated through somatostatin receptors [1,2], but some clinical research have indicated that the impact of somatostatin and its analog receptor expression levels on outcomes in patients with pancreatic neuroendocrine tumors (PNETs) has not been evaluated [3,4]
Summary
The aim of this study is to investigate the expressions of somatostatin receptor (SSTR), SSTR-2, SSTR-3, and SSTR-5, in pancreatic tissue and non-cancerous tissue and elucidate their clinical significance. Full list of author information is available at the end of the article expression of somatostatin receptor subtypes SSTR-2, SSTR-3, and SSTR-5 messenger RNA (mRNA) from 108 cases of cancer tissue and adjacent tissue in patients with pancreatic cancer using RT-PCR method. Thereafter, we explored the clinical implications of somatostatin therapy for patients with pancreatic cancer. Our study is aimed at exploring the cause from different therapeutic effects of somatostatin and its analogs on human pancreatic cancer and their relationship between changes of SSTR-2 gene expression and expression of SSTR-2, SSTR-3, and SSTR-5 genes [5]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
